6533b7ddfe1ef96bd1274950
RESEARCH PRODUCT
RSV disease in infants and young children: Can we see a brighter future?
Eugenio BaraldiGiovanni Checcucci LisiClaudio CostantinoJon H. HeinrichsPaolo ManzoniMatteo RiccòMichelle RobertsNatalya Vassilouthissubject
respiratory syncytial virusImmunologyRSV vaccinesRespiratory Syncytial Virus InfectionsCommunicable DiseasesRSV preventionRSV all infantsImmunology and AllergyHumansChildmonoclonal antibodieRespiratory Tract InfectionsPharmacologyRSV all infantInfant NewbornRSVInfantAntibodies MonoclonalRSV paediatric burdenHospitalizationLRTIRSV epidemiologyChild PreschoolRespiratory Syncytial Virus HumanBronchiolitismonoclonal antibodiesLRTI; RSV; RSV all infants; RSV epidemiology; RSV paediatric burden; RSV prevention; RSV vaccines; monoclonal antibodies; respiratory syncytial virusRSV prevention: RSV vaccines.description
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclonal antibodies to provide rapid long-lasting protection, and pediatric vaccines. RSV has been identified as a major global priority but a solution to tackle this unmet need for all children has yet to be implemented. New technologies represent the avenue for effectively addressing the leading-cause of hospitalization in children <1 years old.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | Human vaccinesimmunotherapeutics |